| Name | Title | Contact Details |
|---|
John J. Morgan and David R. White founded MorganWhiteGroup, Inc. in 1987. The business started out primarily focusing on payroll deduction of supplemental insurance products, and has grown into what is today, a holding company made up of 6 wholly owned subsidiaries. The MorganWhiteGroup of companies now includes: Two sales agencies, MWG Employer Services and MWG Senior Healthcare, two third-party administrators (TPAs), MorganWhite Administrators, Inc. and MorganWhite Administrators International, a marketing agency, MWG Marketing, and a Reinsurance Intermediary, MWG Reinsurance, Inc. Our success since 1987 has been achieved by delivering insurance products to the marketplace that cannot be found anywhere else. Our company's guiding principal has been to find a market that is either under-served or not served at all and design a product to fit that market. At MorganWhiteGroup, we look forward to the challenge of solving customers’ medical, dental and vision insurance needs today, and in the future. We are committed to making the investment in technology, equipment, and personnel to provide our customers with the latest, most up to date tools available, to solve their insurance needs.
Beiersdorf, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Wilton, CT. To find more information about Beiersdorf, Inc., please visit www.bdfusa.com
Lake Superior X-Ray is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
We`re on a mission to make life better for patients taking part in clinical trials around the world, and their caregivers. Our solutions focus on the four key elements of a successful clinical trial: recruitment, engagement, retention and trial outcomes. Combining our in-house technology platforms with 24/7 truly personalised patient care, we focus on creating remarkable patient experiences at every stage of the clinical journey. Remarkable means going above and beyond to support patients in a way that works best for them and their lives. Whether that`s facilitating clinical trial participation in their own homes, supporting them to travel safely to and from study sites, or using technology to manage everything from expense reimbursement to telehealth, we work with our partners to support the protocol design that meets their patient`s needs. Understanding the complexities of the patient journey is paramount to advancing medicine, and exploring digital technology that enables better trial outcomes has never been more important. This all starts with putting patients first in clinical research. When you partner with us, your patients receive a truly remarkable service and your trial outcomes are better.